MediWound Says DSMB Recommends Phase III VALUE Study Of EscharEx Continues Without Modification, No Safety Concerns Identified
Share
Why It Matters
MediWound's big medicine study is moving forward safely. The safety watchers found no problems, which is a good sign for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.